Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPO | P22079 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21130776 | 0.77 | LPO (0.34) | LPOALDH1A1HPGDHSD17B10 | |
| SCHEMBL3532209 | 0.77 | — | — | |
| SCHEMBL27217132 | 0.74 | LPO (0.38) | LPOALDH1A1HPGDHSD17B10F10 | |
| SCHEMBL27217134 | 0.74 | LPO (0.38) | LPOALDH1A1HPGDHSD17B10F10 | |
| SCHEMBL15431994 | 0.74 | F10 (0.40) | LPOALDH1A1HPGDHSD17B10F10 | |
| Hydrochloric Acid SCHEMBL25406317 | 0.73 | LPO (0.40) | LPOALDH1A1HPGDHSD17B10 | |
| SCHEMBL27217166 | 0.73 | CCNE1 (0.41) | LPOALDH1A1F10 | |
| SCHEMBL30660177 | 0.73 | LPO (0.40) | LPOALDH1A1HPGDHSD17B10F10 | |
| SCHEMBL14960627 | 0.73 | ALDH1A1 (0.41) | LPOALDH1A1HPGDHSD17B10F10 | |
| SCHEMBL7457735 | 0.72 | LPO (0.39) | LPOALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308139-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308139-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | LPO 312/4885ALDH1A1 411/4885HPGD 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.